David Mahvi to Genetic Therapy
This is a "connection" page, showing publications David Mahvi has written about Genetic Therapy.
Connection Strength
0.786
-
Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther. 2002 Sep; 1(11):949-57.
Score: 0.175
-
B7.1 expression eliminates tumor resistance to IL-12 gene therapy. Cancer Gene Ther. 2001 Feb; 8(2):118-27.
Score: 0.156
-
Interleukin-12 gene transfer results in CD8-dependent regression of murine CT26 liver tumors. Ann Surg Oncol. 1999 Mar; 6(2):186-94.
Score: 0.137
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther. 1999 Jan-Feb; 6(1):81-8.
Score: 0.135
-
Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther. 2003 Jul 20; 14(11):1037-48.
Score: 0.046
-
Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer. Hum Gene Ther. 2001 Jan 20; 12(2):149-60.
Score: 0.039
-
Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13351-6.
Score: 0.036
-
DNA cancer vaccines: a gene gun approach. Immunol Cell Biol. 1997 Oct; 75(5):456-60.
Score: 0.031
-
Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther. 1997 May 01; 8(7):875-91.
Score: 0.030